Carsten Saft

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4303052/publications.pdf

Version: 2024-02-01

71 papers	1,727 citations	257101 24 h-index	301761 39 g-index
75 all docs	75 docs citations	75 times ranked	2392 citing authors

#	Article	IF	Citations
1	Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Movement Disorders, 2005, 20, 674-679.	2.2	162
2	Treating the whole body in Huntington's disease. Lancet Neurology, The, 2015, 14, 1135-1142.	4.9	126
3	PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Molecular Neurodegeneration, 2011, 6, 32.	4.4	106
4	Patterns of CAG repeat instability in the central nervous system and periphery in Huntingtonâ€™s disease and in spinocerebellar ataxia type 1. Human Molecular Genetics, 2020, 29, 2551-2567.	1.4	69
5	Time Processing in Huntington's Disease: A Group-Control Study. PLoS ONE, 2007, 2, e1263.	1.1	65
6	NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Human Genetics, 2007, 122, 175-182.	1.8	64
7	fMRI reveals altered auditory processing in manifest and premanifest Huntington's disease. Neuropsychologia, 2008, 46, 1279-1289.	0.7	64
8	A protein quality control pathway regulated by linear ubiquitination. EMBO Journal, 2019, 38, .	3.5	63
9	Upper gastrointestinal findings in Huntingtonâ€™s disease: patients suffer but do not complain. Journal of Neural Transmission, 2009, 116, 1607-1611.	1.4	58
10	Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. Journal of Molecular Medicine, 2010, 88, 431-436.	1.7	56
11	Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. BMC Neurology, 2006, 6, 11.	0.8	55
12	Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology, 2013, 80, 743-746.	1.5	52
13	Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. Journal of Psychiatry and Neuroscience, 2011, 36, 187-194.	1.4	51
14	Impaired motor speech performance in Huntingtonâ€™s disease. Journal of Neural Transmission, 2014, 121, 399-407.	1.4	48
15	A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntingtonâ€™s Disease. Frontiers in Neurology, 2015, 6, 177.	1.1	47
16	Huntington's disease as caused by 34 CAG repeats. Movement Disorders, 2008, 23, 879-881.	2.2	46
17	Laquinimod treatment in the R6/2 mouse model. Scientific Reports, 2017, 7, 4947.	1.6	36
18	Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1210-1220.	3.3	34

#	Article	IF	Citations
19	Assessment of simple movements reflects impairment in Huntington's disease. Movement Disorders, 2006, 21, 1208-1212.	2.2	33
20	Cannabinoids for Treatment of Dystonia in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2018, 7, 167-173.	0.9	33
21	Assessment of complex movements reflects dysfunction in Huntington?s disease. Journal of Neurology, 2003, 250, 1469-1474.	1.8	29
22	Better global and cognitive functioning in choreatic versus hypokineticâ€rigid Huntington's disease. Movement Disorders, 2013, 28, 1142-1145.	2.2	29
23	Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease. Experimental Neurology, 2016, 285, 12-23.	2.0	28
24	Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease. Movement Disorders, 2014, 29, 831-834.	2.2	27
25	Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Experimental Neurology, 2014, 257, 50-56.	2.0	25
26	Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology, 2016, 86, 1329-1335.	1.5	23
27	Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease. Experimental Neurology, 2018, 302, 112-128.	2.0	20
28	Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series. Brain Sciences, 2020, 10, 340.	1.1	19
29	Objective assessment of gait and posture in premanifest and manifest Huntington disease â€" A multi-center study. Gait and Posture, 2018, 62, 451-457.	0.6	18
30	Mentalizing in preclinical Huntingtonâ€™s disease: an fMRI study using cartoon picture stories. Brain Imaging and Behavior, 2013, 7, 154-162.	1.1	16
31	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. Movement Disorders, 2019, 34, 584-585.	2.2	16
32	Hepatic mitochondrial dysfunction in Friedreich Ataxia. BMC Neurology, 2011, 11, 145.	0.8	15
33	Association of CAG Repeat Length in the Huntington Gene With Cognitive Performance in Young Adults. Neurology, 2021, 96, e2407-e2413.	1.5	12
34	Oral and dental health in Huntingtonâ€˜s disease - an observational study. BMC Neurology, 2013, 13, 114.	0.8	11
35	Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data. Journal of Neurology, 2018, 265, 1573-1579.	1.8	11
36	Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene. PLoS ONE, 2015, 10, e0131573.	1.1	11

#	Article	IF	Citations
37	Post pump chorea in a 77-year-old male. Neurological Sciences, 2011, 32, 699-701.	0.9	10
38	Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntingtonâ€™s Diseaseâ€”Data from a Real World Cohort. Brain Sciences, 2021, 11, 413.	1.1	10
39	Another Perspective on Huntingtonâ€™s Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD. Brain Sciences, 2021, 11, 1621.	1.1	10
40	Time will tell: Decision making in premanifest and manifest Huntingtonâ€™s disease. Brain and Behavior, 2020, 10, e01843.	1.0	9
41	Altered thirdâ€party punishment in Huntington's disease: A study using neuroeconomic games. Brain and Behavior, 2021, 11, e01908.	1.0	9
42	Transcript-Specific Loss-of-Function Variants in VPS16 Are Enriched in Patients With Dystonia. Neurology: Genetics, 2022, 8, e644.	0.9	9
43	Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokineticâ€rigid motor subtypes in Huntington's disease. Brain and Behavior, 2020, 10, e01704.	1.0	8
44	Echogenicity of basal ganglia structures in different Huntingtonâ€™s disease phenotypes. Journal of Neural Transmission, 2015, 122, 825-833.	1.4	7
45	Does arterial hypertension influence the onset of Huntington's disease?. PLoS ONE, 2018, 13, e0197975.	1.1	6
46	Benign hereditary chorea as an experimental model to investigate the role of medium spiny neurons for response adaptation. Neuropsychologia, 2014, 59, 124-129.	0.7	5
47	Progressive spinal cord atrophy in manifest and premanifest Huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 614-616.	0.9	5
48	No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset. Brain and Behavior, 2022, 12, e2592.	1.0	5
49	Supracubital perineurioma misdiagnosed as carpal tunnel syndrome: case report. BMC Neurology, 2004, 4, 19.	0.8	4
50	Clinical utility gene card for: Huntingtonâ€™s disease. European Journal of Human Genetics, 2014, 22, 713-713.	1.4	4
51	What is the course of Huntington's disease?. Lancet Neurology, The, 2014, 13, 1165-1166.	4.9	4
52	Teaching Video NeuroImages: New STUB1 Variant Causes Chorea, Tremor, Dystonia, Myoclonus, Ataxia, Depression, Cognitive Impairment, Epilepsy, and Superficial Siderosis. Neurology, 2021, 97, 10.1212/WNL.0000000000012264.	1.5	4
53	Differential Diagnosis of Choreaâ€”HIV Infection Delays Diagnosis of Huntingtonâ€™s Disease by Years. Brain Sciences, 2021, 11, 710.	1.1	4
54	No evidence of impaired gastric emptying in early Huntingtonâ€˜s Disease. PLOS Currents, 2011, 3, RRN1284.	1.4	4

#	Article	IF	Citations
55	Diadochokinetic movements differ between patients with Huntington's disease and controls. NeuroRehabilitation, 2013, 33, 649-655.	0.5	3
56	Obsessive-Compulsive Symptoms are Less Common in Huntingtonâ€™s Disease than Reported Earlier. Journal of Huntington's Disease, 2019, 8, 493-500.	0.9	3
57	Emergence of Bruxism after Reducing Left Pallidal Stimulation in a Patient with Huntington's Disease. Movement Disorders Clinical Practice, 2020, 7, 704-705.	0.8	3
58	Correspondence on â€œClinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairmentâ€•by Roux et al.. Genetics in Medicine, 2021, 23, 1171-1172.	1.1	2
59	J01â€…Effects of IONIS-HTTRX (RG6042) in patients with early huntingtonâ€™s disease, results of the first htt-lowering drug trial. , 2018, , .		2
60	Antiepileptic effects of cobalt, manganese and magnesium on bicuculline-induced epileptiform activity in hippocampal neurons. Brain Research, 2020, 1732, 146684.	1.1	2
61	High noon back pain- severe pseudoradicular pain as a lead symptom of superficial siderosis: a case report. Therapeutic Advances in Neurological Disorders, 2014, 7, 276-278.	1.5	1
62	L22â€…Intranasal application of NPY and NPY13â€“36 ameliorate disease pathology in R6/2 mouse model of huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A97.2-A98.	0.9	1
63	Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology, 2016, 87, 2283-2283.	1.5	1
64	Tit for Tat: Costly Punishment in Manifest Huntingtonâ€™s Disease. Neurodegenerative Diseases, 2021, 21, 74-78.	0.8	1
65	Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntingtonâ€™s Disease. Biomedicines, 2022, 10, 1258.	1.4	1
66	Resurrection of sildenafil: potential for Huntingtonâ€™s Disease, too?. Journal of Neurology, 2022, 269, 5144-5150.	1.8	1
67	L7â€…Laquinimod in the R6/2 mouse model of huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A92.2-A92.	0.9	0
68	E2â€…Progression of motor subtypes in huntingtonâ€™s disease: a six-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A45.2-A45.	0.9	0
69	Identifying modifiers of Huntington's disease progression. Lancet Neurology, The, 2017, 16, 679-680.	4.9	0
70	Functional Connectivity During Auditory Processing in Huntingtonâ€™s Disease. Journal of Psychophysiology, 2008, 22, 195-201.	0.3	0
71	P 329. Patients with Juvenile Huntingtonâ€™s Disease Benefit from Early Diagnosis. Neuropediatrics, 2018, 49, .	0.3	0